TauRx Therapeutics Achieves Enrolment Target for Second Phase III Clinical Trial of LMTX™ in Alzheimer’s Disease

Sep 22 - 2014 04:28 AM

TauRx Therapeutics Ltd has achieved its target enrolment of 700 subjects with mild Alzheimer’s disease into the second of its two Phase III clinical trials of LMTX™, a tau aggregation inhibitor, for the treatment of Alzheimer’s disease.

Read more


TauRx Therapeutics Achieves Enrolment Target in the First of its Two Phase III Clinical Trials of LMTX™ in Alzheimer’s Disease

Jul 15 - 2014 12:00 AM

TauRx Therapeutics Ltd today announced it has achieved its target enrolment of 833 subjects into one of its two ongoing multi-centre Phase III clinical trials of LMTX™, a tau aggregation inhibitor, for the treatment of Alzheimer’s Disease [AD].

Read more


FTD Global Study Locator

Apr 04 - 2014 12:00 AM

Read more


TauRx Chairman to present at scientific symposium focused on advances in Alzheimer’s treatments

Mar 26 - 2014 12:00 AM

Prof. Wischik, Chairman of TauRx Therapeutics, will present a scientific update at the 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy on the company’s global Phase 3 clinical trials; its tau aggregation inhibitor, LMTX™, is aimed at halting the progression of Alzheimer’s

Read more


TauRx Therapeutics to present at Social Care Conference in London on 25th March

Mar 23 - 2014 12:00 AM

TauRx Chairman and London-based principal investigator will highlight how access to investigational treatments for Alzheimer’s is changing the care model for people with cognitive impairment – now and in the future

Read more


Erste deutsche Patienten melden sich zu den klinischen Phase-3-Studien von LMTX™ zur Alzheimer-Krankheit an

Jan 09 - 2014 02:46 AM

Klinische Studien beginnen in Deutschland mit einem Tau-Aggregationshemmer (TAI) der zweiten Generation mit dem Ziel, das Fortschreiten von Alzheimer zu stoppen

Read more


First German patients enroll in Phase 3 clinical trials of LMTX™ for Alzheimer’s Disease

Jan 08 - 2014 12:00 AM

Clinical trials get under way in Germany with a second-generation tau aggregation inhibitor (TAI) aimed at halting the progression of Alzheimer’s

Read more


TauRx Expands Alzheimer’s Clinical Trials in the United States

Jan 05 - 2014 12:00 AM

Clinical research centers added to allow more patients to access a tau-based investigational treatment for mild to moderate Alzheimer’s disease

Read more


Chairman of TauRx and Dr Emer MacSweeney of Re:Cognition Health to speak at ADI Middle East Conference in Dubai on 8-9 December

Dec 06 - 2013 10:54 AM

Two innovative UK thought leaders in Alzheimer’s disease will be speaking at the upcoming 2nd Middle East and North Africa Conference of Alzheimer's Disease International this weekend.

Read more


In Croatia, three international leaders in Alzheimer’s discuss ongoing clinical trials and global dementia policy ahead of the G8 Dementia Research Summit in London next week

Dec 06 - 2013 10:26 AM

Professor Claude Wischik, Chairman of TauRx Therapeutics, Marc Wortmann, Executive Director of Alzheimer’s Disease International (ADI), and Prof. Ninoslav Mimica, President of Alzheimer Croatia, provide the latest news about ADI’s global dementia policy and the Croatian launch of a global Alzheimer’s Research Study

Read more


FTD Global Study Locator

Alzheimer's Global Study Locator

Genting Invests with TauRx for Stake in Alzheimer's Market Leadership